March 27 (Reuters) - Walgreen WBA.O will pay more than $2.85 million to settle whistleblower allegations that the pharmacy overbilled Medicaid programs in Georgia and Massachusetts for generic medications, the U.S. Department of Justice said on Thursday.
The settlement partially resolves claims against the Walgreens Boots Alliance unit brought under the federal, Georgia and Massachusetts False Claims Act.
Walgreen pharmacies were accused of having from 2008 to 2023 submitted elevated "usual and customary" prices for some generic medications to the MassHealth and Georgia Medicaid programs, causing those programs to pay more for the medications than they should have.
(Reporting by Jonathan Stempel in New York)
((jon.stempel@thomsonreuters.com; +1 646 223 6317; Reuters Messaging: jon.stempel.thomsonreuters.com@reuters.net))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。